Modification of constrained peptides by ring-closing metathesis reaction

Article abstract of DOI:10.1016/S0960-894X(01)00227-X

Ring-closing metathesis (RCM) with α,α-diallylglycyl peptides is shown to furnish α,α-cyclopentenylglycyl peptides as conformationally restrained analogues in the form of post-translational type peptide modification suitable for both peptidomimetic and co

Full text of DOI:10.1016/S0960-894X(01)00227-X

Bioorganic & Medicinal Chemistry Letters 11 (2001) 1421–1423
Modification of Constrained Peptides by Ring-Closing Metathesis
Reactiony
Sambasivarao Kotha,* Nampally Sreenivasachary, Kumar Mohanraja
and Susheel Durani
Department of Chemistry, Indian Institute of Technology-Bombay, Mumbai 400 076, India
Received 4 January 2001; accepted 31 March 2001
Abstract—Ring-closing metathesis (RCM) with a,a-diallylglycyl peptides is shown to furnish a,a-cyclopentenylglycyl peptides as
conformationally restrained analogues in the form of post-translational type peptide modification suitable for both peptidomimetic
and combinatorial chemistry applications. # 2001Elsevier Science Ltd. All rights reserved.
Peptides, because of their potent physiological activities,
are valuable lead compounds in drug discovery
research, requiring molecular re-engineering to improve
properties like oral absorptivity, metabolic stability,
function specificity, etc., without compromising the
pharmacological activity of the parent pharmacophore.1
Combinatorial chemistry has emerged as a powerful
adjunct to peptidomimetic chemistry that aims to
harness the peptidic pharmacophores in alternative
conformationally restrained molecular frameworks. The
value of combinatorial chemistry in peptidomimetic
applications is likely to be enhanced by methodologies
wherein precursor peptides, made by conventional pep-
tide chemistry methodology, may be modified in a post-
translational type manner,2 resulting in structurally cri-
tical side-chain elements to be incorporated into rigid
molecular frame works. Although ring-closing metath-
esis (RCM) reaction is applied to the readily available
O-alkylated or N-alkylated peptides, the RCM of aa-
dialkylated peptides is not known in the literature.
Moreover, synthesis of aa-dialkylated peptides is not
a trivial exercise. Motivated by such a need for post-
translational type peptide modification strategies
suitable for combinatorial chemistry research,3 we
have explored RCM as a possible reaction.4 Herein,
we demonstrate the application of RCM strategy to
produce a,a-cyclic peptides with restrained conformations
for the first time.
Allylation of the ethyl isocyanoacetate 1, under phase
transfer catalysis (PTC) conditions (tetrabutylammonium
hydrogensulphate, K2CO3, CH3CN) gave the diallyl-
ated product 2 in 80% yield (Scheme 1)5 which, on
treatment with a few drops of concentrated HCl in
absolute ethanol, gave the amino ester 3 in 95% yield.
The reaction of 3 with Boc anhydride in refluxing
chloroform gave the Boc derivative 4 in 96% yield.
(Scheme 1). Hydrolysis of the Boc protected ester 4 with
1N NaOH in dioxane gave the acid derivative 5 (99%).
The IR spectrum of 5 showed a characteristic absorp-
tion band at 1789 and 3505 cmÀ1 due to the carboxylic
group. The 1H NMR spectrum showed a broad signal at
d 8.44 due to the carboxylic proton, and a characteristic
singlet at d 1.43 due to Boc group, and multiplets at d
5.11–5.16 and 5.16–5.76 due to the olefin functionality
confirm the formation of the product 5.
*Corresponding author. Tel.: +91-22-576-7160; fax: +91-22-572-
3480; e-mail: srk@chem.iitb.ac.in
yA portion of the work was presented at the 8th National Organic
Symposium Trust Meeting (NOST), Jaipur, 2–5 March, 2000: Kotha,
S. Olefin Metathesis in Organic Synthesis.
Scheme 1. Reagents: (i) allyl bromide, K2CO3, PTC; (ii) HCl, EtOH;
(iii) (Boc)2O/CHCl3; (iv) 1N NaOH/dioxane; (v) HClH 2NPheOMe,
DCC, HOBt, NMM, THF; (vi) Grubbs catalyst/CH2Cl2.
0960-894X/01/$ - see front matter # 2001Elsevier Science Ltd. All rights reserved.
PII: S0960-894X(01)00227-X

1422
S. Kotha et al. / Bioorg. Med. Chem. Lett. 11 (2001) 1421–1423
Table 1.
S. No.
Peptide
RCM product
Yielda (%)
75
1
2
3
4
5
6
7
90
50
49
53
75
69
aYield refers to the yield of the RCN reaction.
Later on, we turned our attention to couple compound
5 with various proteinogenic a-amino acid (AAA) deri-
vatives. In this regard, the reaction of 5 with the
phenylalanine methyl ester hydrochloride in the pre-
sence of DCC/HOBt gave the dipeptide 6 in 63% yield
(Scheme 1).6 Along similar lines we have also prepared
the compound 12 (Table 1).
derivatives by the RCM reaction in post-translational
modification form. Since aa-dialkylated constrained
peptides play an important role in peptidomimetics, our
approach for modification of aa-dialkylated peptides is
unique and possible incorporation of the present
method into combinatorial chemistry format should be
of interest to bioorganic and medicinal chemists want-
ing to modify peptides in a peptidomimetic application.
The structure of 6 was fully in consonance with its
spectral data. Various peptide couplings of the key
building block 5 with other proteinogenic AAAs have
been performed using the standard DCC-mediated
coupling conditions.
General Experimental Procedure for the RCM Reaction
To the dipeptide 6 (30 mg, 0.074 mmol) in toluene (3.5
mL) was added Grubbs catalyst [Cl2(PCy3)2Ru¼CHPh]
(10% mol) and then the reaction mixture was refluxed
for 12 h. Then, the reaction mixture was concentrated
and the crude product was purified by a silica gel col-
umn (1:4 ethyl acetate–hexane) to give 13 as a white
crystalline solid (21 mg, 75%). Mp 162–163 ꢀC; [a]D26
+2.40 (c 1, EtOH); 1H NMR (300 MHz, CDCl3): d 1.41
(s, 9H), 2.72–2.91(m, 4H), 3.07 (d 1 =2ABq, J=6.6, 14.0
Hz, 1H), 3.15 (d 1=2ABq, J=5.7, 6.0, 14.0 Hz, 1H), 3.71
(s, 3H), 4.83 (1=2ABq, J=5.7, 6.3 Hz, 1H), 5.47 (s, 1H),
5.57 (s, 2H), 6.66 (s, 1H), 7.08–7.11 (m, 2H), 7.21–7.31
(m, 3H); HRMS m/z for C21H28N2O5 (MÀC4H9), calcd
332.1372. Found 332.1357.
Having prepared the unsaturated building blocks 6–12
(Table 1), attention was then focused to carry out the
RCM reaction. Thus, treatment of the dipeptide 6 with
the Grubbs ruthenium catalyst [Cl2(PCy3)2Ru¼CHPh]
in refluxing toluene gave the RCM product 13 in 75%
yield (Scheme 1). Similarly, the exposure of the other
peptide building blocks (7–12) to Grubbs catalyst condi-
tions gave the corresponding cyclized products (14–19) in
good yields and the results are summarized in Table 1.
In conclusion, for the first time we have developed a
simple method for the preparation of cyclic peptide

S. Kotha et al. / Bioorg. Med. Chem. Lett. 11 (2001) 1421–1423
1423
Spectral Data for Selected Compounds
4.86 (dd, J=6.3, 7.5 Hz, 1H), 5.67 (s, 2H), 7.11 (s, 1H),
7.11–7.24 (5H). HRMS: m/z for C23H32N2O5
(MÀOC2H5), calcd 360.1658. Found 360.1667.
14. Mp 123–124 ꢀC; [a]2D6 +2.85 (c 0.7, EtOH); 1H
NMR (300 MHz, CDCl3): d 0.86 (d, J=7.2 Hz 3H),
0.95 (d, J=6.9 Hz, 3H), 1.43 (s, 9H), 2.15–2.19 (m, 1H),
2.80–3.08 (m, 2H), 3.09–3.14 (m, 2H), 3.72 (s, 3H), 4.54
(dd, J=4.8, 8.7 Hz, 1H), 5.37 (s, 1H), 5.70–5.75 (m,
2H), 6.86 (s, 1H).
Acknowledgements
We are thankful to DST, New Delhi for the financial
support. NS and KM thank CSIR, New Delhi, and IIT-
Bombay for the award of Fellowships. We also thank
RSIC-Mumbai for the spectral data.
1
15. [a]2D6 +14.44 (c 1.8, EtOH); H NMR (300 MHz,
CDCl3): d 0.91(d, J=4.2 Hz, 6H), 1.30–1.40 (m, 3H),
1.43 (s, 9H), 1.50–1.75 (m, 3H), 2.56–2.66 (m, 2H),
3.03–3.08 (m, 2H), 3.73 (s, 3H), 4.43–4.58 (m, 2H), 5.25
(s, 1H), 5.69 (s, 2H), 6.79 (d, J=6.9 Hz, 1H), 6.87
(s, 1H); HRMS: for m/z C21H35N3O6, calcd 425.2525.
Found 425.2505.
References and Notes
1. Fletcher, M. D.; Campbell, M. M. Chem. Rev. 1998, 98,
763. Marshall, G. R. Tetrahedron 1993, 49, 3547. Gante, J.
Angew. Chem., Int. Ed. Engl. 1994, 33, 1699. Goodman, M.;
Shao, H. Pure Appl. Chem. 1996, 68, 1303. Hanessian, S.;
Mcnaughton-Smith, G.; Lombart, H. G.; Lubell, W. D.
Tetrahedron 1997, 53, 12789. Liskamp, R. M. J. In Organic
Synthesis Highlights; Muller, J., Waldman, H., Eds.; Wein-
heim: New York, 1991; Vol. 3, pp 366–373.
2. Seebach, D.; Beck, A. K.; Studer, A. In Modern Synthetic
Methods; Ernst, B., Leumann, C., Eds.; VCH: Weinheim,
1995: Vol. 7, p 1, and references cited therein. Apitz, G.; Jager,
M.; Jaroch, S.; Kratzel, M.; Schafferler, L.; Steglich, W. Tet-
rahedron 1993, 49, 8223. Easton, C. J.; Scharfbilling, I. M.;
Tan, E. W. Tetrahedron Lett. 1988, 29, 1565. Ranganathan,
D.; Vaish, N. K.; Shah, K. J. Am. Chem. Soc. 1994, 116, 6545.
Yousaf, M. N.; Mrksich, M. J. Am. Chem. Soc. 1999, 121,
4286.
3. Kotha, S.; Brahmachary, E. Tetrahedron Lett. 1997, 38,
3561. Kotha, S.; Brahmachary, E. Bioorg. Med. Chem. Lett.
1997, 8, 2719. Kotha, S.; Sreenivasachary, N. Bioorg. Med.
Chem. Lett. 1998, 8, 257. Kotha, S.; Sreenivasachary, N. J.
Chem. Soc., Chem. Commun. 2000, 503. Kotha, S.; Sreeniva-
sachary, N. Bioorg. Med. Chem. Lett. 2000, 10, 1413.
4. Schmaltz, H. G. Angew. Chem., Int. Ed. Engl. 1995, 34,
1833. Schuster, M.; Blechert, S. Angew. Chem., Int. Ed. Engl.
1997, 36, 2036. Grubbs, R. H.; Chang, S. Tetrahedron 1998,
54, 4413. Phillips, A. J.; Abell, A. D. Aldrichimica Acta 1999,
32, 75. Reichwein, J. F.; Liskamp, R. M. J. Eur. J. Org. Chem.
2000, 2335, and references cited therein.
5. Kotha, S.; Brahmachary, E. J. Org. Chem. 2000, 65, 1359.
6. Bodansky, M.; Bodansky, A. In The Practice of Peptide
Synthesis; Hafner, K., Rees, C. W., Trost, B. M., Lehn, J.-M.,
Schleyer, P. R., Zahradnik, R., Eds.; Springer: New York,
1984. Anderson, G. W.; Mcgregor, A. C. J. Am. Chem. Soc.
1957, 79, 6180.
16. [a]2D6 À34.16 (c 1.2, EtOH); 1H NMR (300 MHz,
CDCl3): d 0.91–0.94 (m, 6H), 1.39–1.41 (m, 3H), 1.43 (s,
9H), 1.51–1.73 (m, 3H), 2.55–2.66 (m, 2H), 3.03–3.12
(m, 2H), 3.73 (s, 3H), 4.42–4.45 (m, 2H), 5.23 (s, 1H),
5.69 (s, 2H), 6.61(d, J=8.1 Hz, 1H), 6.97 (s, 1H);
HRMS: m/z for C21H35N3O6 (MÀC4H9), calcd
369.1899. Found 369.1909.
17. Mp 138–139 ꢀC; [a]2D6 À18.49 (c 2, EtOH); 1H NMR
(300 MHz, CDCl3): d 0.90–0.99 (m, 12H), 1.44 (s, 9H),
2.15–2.23 (m, 1H), 2.36–2.38 (m, 1H), 2.53–2.60 (m,
2H), 3.03–3.19 (m, 2H), 3.70 (s, 3H), 4.30 (dd, J=4.5,
7.9 Hz, 1H), 4.45 (dd, J=5.7, 8.4 Hz, 1H), 5.22 (s, 1H),
5.65–5.72 (m, 2H), 6.76 (d, J=6.0 Hz 1H), 6.95
(d, J=7.2 Hz, 1H). HRMS: m/z for C22H37N3O6
(MÀC4H9), calcd 383.2056. Found 383.2065.
18. [a]2D6 +7.33 (c 1.5, EtOH); 1H NMR (300 MHz,
CDCl3): d 0.85–0.99 (m, 12H), 1.44 (s, 9H), 1.59–1.77
(m, 3H), 2.54 (1=2 ABq, J=16.5 Hz, 2H), 2.57 (1=2
ABq, J=18.0 Hz, 1H), 2.94 (1=2 ABq, J=17.1 Hz, 1H),
3.34 (1=2 ABq, J=17.4 Hz, 1H), 3.67 (s, 3H), 4.30 (dd,
J=3.9, 8.1 Hz, 1H), 4.47–4.54 (m, 1H), 5.22 (s, 1H),
5.70 (d, J=34.0, 2H), 6.67 (d, J=6.0 Hz, 1H), 7.30 (d,
J=6.9 Hz, 1H); HRMS: m/z for C23H39N3O6
(MÀC2H4), calcd 425.2505. Found 425.2525.
1
19. IR (neat): nmax 3340 (NH), 1736 (CO2Et) cmÀ1; H
NMR (300 MHz, CDCl3): d 1.41 (s, 9H), 2.00–2.22
(8H), 3.12 (d, J=5.7 Hz, 2H), 3.68 (s, 3H), 4.73 (s, 1H),